OSE-172 (Effi-DEM), a new generation checkpoint inhibitor, targets particular suppressor cells present in the tumor microenvironment and which are associated with a poor prognosis, as they lead to tumor growth. These cells are “Myeloid-Derived Suppressor Cells” (MDSC) and macrophage cells associated with tumors called “Tumor Associated Macrophages” (TAM).
OSE-172 blocks the SIRP-alpha receptor (Signal Regulatory Protein Alpha). This blockage transforms MDSC and TAM into non suppressor cells, thus blocking tumor growth.
OSE-172 targets cancers that express key cells of inflammatory cancer progression, i.e. TAM and MDSC cells. These types of cancer, including primary liver cancer or colon cancer, are linked to a chronic inflammation.
OSE Immunotherapeutics Siège social
22, boulevard Benoni Goullin
Tel. :+33 (0)2 28 29 10 10 firstname.lastname@example.org
En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour réaliser des statistiques anonymes de visites. Vous pouvez vous y opposer en les désactivant. Pour cela, vous devez cliquer sur "NON".